Japan: Researchers have found in a new study that Roxadustat therapy in non-dialyzed chronic kidney disease (CKD) patients ...

Peginesatide (Omontys, Affymax), a peptide-based ESA, 9,10 was approved in the United States in March 2012 for the treatment of anemia caused by chronic kidney disease in adults who are undergoing ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.28±0.02 g per deciliter with daprodustat and 0.10±0.02 g per deciliter with ESA therapy, for a ...

There are more than 700,000 prevalent cases of end-stage kidney disease in the United States, which is increasing by approximately 20,000 cases per year.1 Peritoneal dialysis is a home renal ...

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

INNO 2 VATE-2 included patients on chronic maintenance dialysis for more than 12 weeks who had converted from prior ESA therapy. The coprimary endpoints were the mean change in hemoglobin (Hb ...